CN110297050A - A kind of discrimination method of insulin mass spectrum peptide figure and application - Google Patents
A kind of discrimination method of insulin mass spectrum peptide figure and application Download PDFInfo
- Publication number
- CN110297050A CN110297050A CN201910663742.5A CN201910663742A CN110297050A CN 110297050 A CN110297050 A CN 110297050A CN 201910663742 A CN201910663742 A CN 201910663742A CN 110297050 A CN110297050 A CN 110297050A
- Authority
- CN
- China
- Prior art keywords
- insulin
- enzyme
- peptide
- injection
- mass spectrum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
- G01N2030/067—Preparation by reaction, e.g. derivatising the sample
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/884—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample organic compounds
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a kind of discrimination method of insulin mass spectrum peptide figure and applications.The present invention is combined using V8 enzyme combination V8 enzyme and lysyl endopeptidase, specific for hydrolysis insulin, establishes the peptide figure containing insulin characteristic fragments by LC-MS instrument.Method is established: providing the enzymatic hydrolysis environment of pH7.5~9.5 using buffer, substrate is with enzyme by insulin: V8 enzyme: lysyl endopeptidase ≈ (100~1000): (100~500): 1 mass ratio react overnight, reaction solution dilutes 10~30 times, it is detected using liquid phase separation mass detector, establishes the feature peptide mapping of each kind insulin.Using mass spectrum peptide mapping of the invention, various different insulin can be accurately determined, method is accurate and reliable.
Description
Technical field
The invention belongs to Pharmaceutical Analysis technical field, it is related to a kind of method for building up of insulin enzymatic hydrolysis mass spectrum peptide mapping and answers
With.
Background technique
Insulin type recombinant product is at present for the most effective and safest treatment means of diabetes.Population base of China
Greatly, diabetic's quantity is more, and insulin usage amount is big.Although recombinant technique content is high, production process is complicated, in abundant benefit
Under profit driving, there are the risks that illegal retailer is mixed the spurious with the genuine using animal derived insulin.In present quality standard, for
The identification of the Recombulin true and false is identified using retention time consistency, and variety classes Recombulin is intermolecular
Structure and its similar, retention time is very close, practical to identify in operating process that there is certain difficulties.
Summary of the invention
The object of the present invention is to provide a kind of discrimination methods of insulin mass spectrum peptide figure.The present invention is using suitable enzymatic hydrolysis side
Method is aided with Mass Spectrometer Method, and the enzymatic hydrolysis mass spectrum peptide figure for establishing each para-insulin will greatly improve the accurate reliability of identification, improves pancreas
The distinguishing ability of island element provides strong technical support for the work of cracking down on the fake of insulin.
To achieve the above object, the invention discloses following technology contents:
A kind of discrimination method of insulin mass spectrum peptide figure, it is characterised in that carried out by following step:
(1) identify various para-insulins using V8 enzyme combination V8 enzyme and lysyl endopeptidase combination enzyme solution；
(2) V8 enzyme and lysyl endopeptidase combination enzyme solution identify insulin lispro；
(3) hydrolysising condition: the enzymatic hydrolysis environment of pH7.5~9.5 is provided using Tris-Hcl buffer；
(4) preparation of reaction solution: according to insulin: V8 enzyme: lysyl endopeptidase ≈ (100~1000): (100~500):
1 mass ratio prepares reaction solution respectively；
(5) chromatographic condition: using octadecylsilane chemically bonded silica as filler, using (0.1%~1%) aqueous formic acid as mobile phase
A, acetonitrile are Mobile phase B, and using gradient elution, flow velocity is (0.2~0.6) ml/min, 50~60 DEG C of column temperature, mass detector；
1 eluent gradient elution requirement (volume ratio) of table
(6) measuring method: taking enzymolysis sample to inject LC-MS instrument, carries out data acquisition, measures the mass spectrogram of enzymolysis polypeptide segment.
Discrimination method of the present invention, it is characterised in that establish feature matter of a variety of insulin under two kinds of enzymatic hydrolysis conditions
Peptide figure is composed, is actrapid monotard, insulin aspart, insulin glargine, paddy bad insulin, insulin lispro, pork insulin, ox pancreas islet
Element etc..
The present invention uses mass detector continuous scanning within the scope of 50 ~ 2000Da, formulates the enzymatic hydrolysis matter of a variety of insulin
Compose peptide figure.
According to the present invention measurement insulin mass spectrum peptide figure, part insulin characterising mass spectrometry theoretical fragment result such as the following table 2,
Table 3:
2 insulin V8 enzyme hydrolysis theoretical fragment conclusive table of table
3 insulin of table hydrolyzes theoretical fragment conclusive table under the conditions of V8 enzyme and lysyl endopeptidase are combined
It includes raw material and preparation that insulin mass spectrum peptide mapping of the present invention, which is established,.Wherein Mass Spectrometer Method obtains 4 feature peptides
Section.It is peptide fragment I, peptide fragment II, peptide fragment III, peptide fragment IV respectively.
The present invention further discloses the discrimination methods of insulin mass spectrum peptide figure quickly to identify the insulin true and false (example accurate
Insulin aspart injection is such as pretended to be with pork insulin injection), identify insulin specific category and (passes through the feature of each insulin
Mass spectrum peptide figure to insulin type realize identify) in terms of application.Experimental result is shown: other using mass spectrum peptide illustrated handbook of the invention
Method can accurately identify the true and false and specific category of insulin (see attached drawing 1~4).
It is all kinds of under two kinds of enzymatic hydrolysis conditions of high spot reviews present invention mainly solves the identification of the insulin true and false and classification
The stability and specificity of insulin peptide hydrolysis, main difficult point are the control of enzymatic hydrolysis condition and the inspection of feature peptide hydrolysis
Survey analysis.
Possessed good effect exists the discrimination method of insulin mass spectrum peptide figure disclosed by the invention compared with prior art
In:
(1) present invention establishes related special mass spectrum peptide figure for a variety of different insulin, can in insulin discrimination process
Quickly and accurately to identify the true and false of insulin, while identifying the specific category of insulin.
(2) present invention will no longer compare the retention time of test sample Yu reference substance enzymolysis polypeptide segment, examine using mass spectrum
After surveying device substitution ultraviolet-visible detector progress polypeptide fragment measurement, the feature matter of each insulin peptide hydrolysis will be directly relied on
Spectrum peptide illustrated handbook determines each insulin.
Detailed description of the invention
Fig. 1 recombinant human insulin injection V8 enzyme hydrolysis mass spectrogram
Fig. 2 pork insulin injection V8 enzyme hydrolysis mass spectrogram
Fig. 3 recombinant human insulin injection V8 enzyme and lysyl endopeptidase combination enzymatic hydrolysis mass spectrogram
Fig. 4 Insulin Lispro Injection V8 enzyme and lysyl endopeptidase combination enzymatic hydrolysis mass spectrogram
Fig. 5 insulin aspart injection V8 enzyme hydrolysis mass spectrum peptide figure；
Fig. 6 palms off insulin aspart injection V8 enzyme hydrolysis mass spectrum peptide figure；
Fig. 7 rh-insulin's chromatogram
Fig. 8 pork insulin chromatogram.
Specific embodiment
The present invention is described below by specific embodiment.Unless stated otherwise, technological means used in the present invention
It is method known in those skilled in the art.In addition, embodiment is interpreted as illustrative, it is not intended to limit the present invention
Range, the spirit and scope of the invention are limited only by the claims that follow.To those skilled in the art, without departing substantially from this
Under the premise of invention spirit and scope, to the various changes or change of material component and dosage progress in these embodiments
It belongs to the scope of protection of the present invention.The raw materials used in the present invention and reagent are commercially available.
Tris-Hcl buffer voluntarily configure (weigh trishydroxymethylaminomethane 12.14g, add water 800ml stirring and dissolving,
And it is diluted to 1000ml, pH value is adjusted with 1mol/L hydrochloric acid solution.)
Insulin source is commercially available
V8 enzyme source is commercially available
Lysyl endopeptidase source is commercially available
Experiment uses instrument for UPLC-XEVO G2-XsQTof LC-MS instrument, is equipped with ESI ion source.
Embodiment 1
Rh-insulin, insulin aspart, insulin lispro and pork insulin injection V8 enzyme hydrolysis mass spectrum peptide figure and V8 enzyme
With lysyl endopeptidase combination mass spectrum peptide figure measurement
Respectively take injection liquid samples 1 respectively, be transferred to 15ml centrifuge tube, be suitable for Tris-Hcl buffer adjust sample pH to
8.5, dilution volume to 15ml.
(1) 600 μ l of dilute sample is taken, 200 μ l(1mg/ml of V8 enzyme is added), then 400 μ l Tris- are added in ambient temperature overnight
Hcl buffer；
(2) 600 μ l of dilute sample is taken, 200 μ l(1mg/ml of V8 enzyme is added) and 50 μ l(20 μ g/ml of lysyl endopeptidase),
Then 400 μ l Tris-Hcl buffers are added in ambient temperature overnight.Sample dilutes 20 times before sample introduction.Using Waters ACQUITY
UPLC®CSHTMC18,1.7 μm, 50 × 2.1mm(I.D) chromatographic column according to following table gradient condition is with 0.1% aqueous formic acid
Mobile phase A, acetonitrile are Mobile phase B, 0.4ml/min flow velocity, 60 DEG C of column temperatures, 5 μ l of sample introduction measurement, acquisition ion flow graph；
4 eluent gradient elution requirement (volume ratio) of table
Four characteristic polypeptide fragments that sample digests generation under two kinds of enzymatic hydrolysis conditions are shown in Table 5 and table 6:
54 kinds of insulin V8 enzyme hydrolysis peptide segment tables of table
64 kinds of insulin V8 enzymes of table and lysyl endopeptidase are combined range of hydrolysed peptides segment table
Under the conditions of V8 enzyme and V8 enzyme and lysyl endopeptidase are combined, according to the feature for digesting generation under two kinds of enzymatic hydrolysis conditions
Property peptide fragment can accurately identify the true and false and the specific classification of insulin of various insulin.
Embodiment 2
Rh-insulin and the combination enzymatic hydrolysis mass spectrum peptide figure measurement of Insulin Lispro Injection V8 enzyme and lysyl endopeptidase
Injection liquid samples 1 is respectively taken, 15ml centrifuge tube is transferred to, it is dilute to be suitable for Tris-Hcl buffer adjusting sample pH to 9
Volume is released to 15ml.1000 μ l of dilute sample is taken, 100 μ l(1mg/ml of V8 enzyme is added) and 20 μ l(20 μ of lysyl endopeptidase
G/ml), then 400 μ l Tris-Hcl buffers are added in ambient temperature overnight.Sample dilutes 10 times before sample introduction.According to 1 ladder of embodiment
The measurement of degree condition, using 0.7% aqueous formic acid as mobile phase A, acetonitrile is Mobile phase B, 0.2ml/min flow velocity, 55 DEG C of column temperatures, into
5 μ l of sample acquires ion flow graph；The four characteristic polypeptide fragments generated after sample enzymatic hydrolysis are shown in Table 7:
7 rh-insulin of table and insulin lispro V8 enzyme and lysyl endopeptidase are combined Peptides segment table
Under V8 enzyme and V8 enzyme and lysyl endopeptidase combination enzymatic hydrolysis condition, rh-insulin and insulin lispro can be with
Effectively identified and is distinguished.
Embodiment 3
Insulin aspart injection and personation insulin aspart injection V8 enzyme hydrolysis mass spectrum peptide figure measurement
Injection liquid samples 1 is respectively taken, 15ml centrifuge tube is transferred to, sample pH is adjusted to 7.5 with Tris-Hcl buffer, is diluted
Volume is to 15ml.1000 μ l of dilute sample is taken, 200 μ l(1mg/ml of V8 enzyme is added), then 400 μ l are added in ambient temperature overnight
Tris-Hcl buffer.Sample dilutes 30 times before sample introduction.It is flowing with 0.5% aqueous formic acid according to 1 gradient condition of embodiment
Phase A, acetonitrile are Mobile phase B, 0.6ml/min flow velocity, 50 DEG C of column temperatures, 5 μ l of sample introduction measurement, acquisition ion flow graph.After sample enzymatic hydrolysis
The four characteristic polypeptide fragments generated are shown in Table 8:
8 insulin aspart of table and personation insulin aspart V8 enzyme Peptides segment table
Under V8 enzyme enzymatic hydrolysis condition, insulin aspart and the available effective identification of personation insulin aspart and differentiation.
Recombinant human insulin injection and pork insulin injection chromatogram under 4 liquid phase chromatogram condition of embodiment
One, sample is respectively taken, and each accurate measurement is appropriate, and it is single that about insulin-containing 10 is made in every 1ml with 0.01mol/L hydrochloric acid solution
Position solution, using C18 chromatographic column, with 0.2mol/L sulfate buffer (pH2.3)-acetonitrile (74:26) for mobile phase,
1.0ml/min flow velocity detects under the conditions of 214nm Detection wavelength.Rh-insulin's chromatogram and pork insulin chromatogram are shown in
The following figure Fig. 7 and Fig. 8.
Through embodiment 4 as can be seen that under identical chromatographic conditions, rh-insulin and pork insulin retention time ratio
It is closer to, by embodiment 1 to embodiment 3 it can be seen that the foundation of enzymatic hydrolysis characterising mass spectrometry peptide figure can be identified accurately and effectively
The true and false of insulin and the specific category of insulin, this method avoid due to insulin molecule amount it is close, in identical chromatography
Under the conditions of variety classes insulin retention time it is close, thus a possibility that bringing mistake for result judgement, the side of substantially increasing
The specificity of method.
Claims (5)
1. a kind of discrimination method of insulin mass spectrum peptide figure, it is characterised in that carried out by following step:
(1) identify various para-insulins using V8 enzyme combination V8 enzyme and lysyl endopeptidase combination enzyme solution；
(2) V8 enzyme and lysyl endopeptidase combination enzyme solution identify insulin lispro；
(2) hydrolysising condition: using the enzymatic hydrolysis environment of pH of buffer 7.5~9.5；The buffer refers to that Tris-Hcl is buffered
Liquid；
(3) preparation of reaction solution: according to insulin: V8 enzyme: lysyl endopeptidase ≈ (100~1000): (100~500):
1 mass ratio prepares reaction solution respectively；
(4) chromatographic condition: being stream with 0.1%~1% aqueous formic acid of volume ratio using octadecylsilane chemically bonded silica as filler
Dynamic phase A, acetonitrile is Mobile phase B, and using gradient elution, flow velocity is 0.2~0.6ml/min, 50~60 DEG C of column temperature, Mass Spectrometer Method
Device；
(5) chromatography gradient condition is as follows:
1 eluent gradient elution requirement (volume ratio) of table
(6) measuring method: taking enzymolysis sample to inject LC-MS instrument, carries out data acquisition, measures the mass spectrogram of enzymolysis polypeptide segment.
2. discrimination method described in claims 1, it is characterised in that feature matter of a variety of insulin under two kinds of enzymatic hydrolysis conditions
Peptide figure is composed, is actrapid monotard, insulin aspart, insulin glargine, paddy bad insulin, insulin lispro, pork insulin, ox pancreas islet
Element.
3. discrimination method described in claims 1, it is characterised in that it includes raw material and preparation that insulin mass spectrum peptide mapping, which is established,；
The raw material and preparation refers to: recombinant insulinum primary material, biosynthetic human insulin injection, protamine biosynthesis
Human insulin injection, protamine biosynthetic human insulin injection (premix 30R), protamine biosynthetic human insulin note
Penetrate liquid (premix 50R), insulin aspart raw material, insulin aspart injection, 30 injection of insulin aspart, insulin aspart 50
Injection.
4. discrimination method described in claims 1, it is characterised in that Mass Spectrometer Method obtains feature peptide fragment.
5. the discrimination method of insulin mass spectrum peptide figure described in claims 1 quickly identifies the insulin true and false accurate, identify pancreas
Application in terms of the element specific category of island.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910663742.5A CN110297050B (en) | 2019-07-23 | 2019-07-23 | Identification method and application of insulin mass spectrum peptide map |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910663742.5A CN110297050B (en) | 2019-07-23 | 2019-07-23 | Identification method and application of insulin mass spectrum peptide map |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110297050A true CN110297050A (en) | 2019-10-01 |
| CN110297050B CN110297050B (en) | 2022-04-12 |
Family
ID=68031625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910663742.5A Active CN110297050B (en) | 2019-07-23 | 2019-07-23 | Identification method and application of insulin mass spectrum peptide map |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110297050B (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111351880A (en) * | 2020-04-01 | 2020-06-30 | 上海中科新生命生物科技有限公司 | Mass spectrum detection method for recombinant human insulin biological analysis based on immunoaffinity |
| CN111778231A (en) * | 2020-07-29 | 2020-10-16 | 珠海冀百康生物科技有限公司 | Purification method of lysyl endopeptidase |
| CN111948315A (en) * | 2020-08-13 | 2020-11-17 | 中国科学院长春应用化学研究所 | Sequence analysis method and identification method of insulin or insulin analogue |
| CN112763636A (en) * | 2020-12-07 | 2021-05-07 | 佛山汉腾生物科技有限公司 | Peptide map analysis method |
| CN115808484A (en) * | 2023-01-18 | 2023-03-17 | 北京惠之衡生物科技有限公司 | Method for detecting residual lysyl endonuclease in insulin or insulin analogue |
| CN116046947A (en) * | 2023-01-28 | 2023-05-02 | 北京惠之衡生物科技有限公司 | Method for detecting residual lysyl endonuclease in insulin diglucer |
| CN116908321A (en) * | 2023-06-21 | 2023-10-20 | 南京汉欣医药科技有限公司 | Protamine sulfate peptide map detection method |
| CN116908321B (en) * | 2023-06-21 | 2024-05-31 | 南京汉欣医药科技有限公司 | Protamine sulfate peptide map detection method |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103392219A (en) * | 2010-12-28 | 2013-11-13 | 探索诊断投资公司 | Quantitation of insulin by mass spectrometry |
| CN105301125A (en) * | 2015-09-11 | 2016-02-03 | 东阿阿胶股份有限公司 | Method for identifying main deamination product site of recombinant human insulin or similar matter thereof |
| CN108896682A (en) * | 2018-07-18 | 2018-11-27 | 杭州汇健科技有限公司 | A kind of quick mass spectral analysis of peptide fingerprinting spectrum and spectrogram method of discrimination |
-
2019
- 2019-07-23 CN CN201910663742.5A patent/CN110297050B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103392219A (en) * | 2010-12-28 | 2013-11-13 | 探索诊断投资公司 | Quantitation of insulin by mass spectrometry |
| CN105301125A (en) * | 2015-09-11 | 2016-02-03 | 东阿阿胶股份有限公司 | Method for identifying main deamination product site of recombinant human insulin or similar matter thereof |
| CN108896682A (en) * | 2018-07-18 | 2018-11-27 | 杭州汇健科技有限公司 | A kind of quick mass spectral analysis of peptide fingerprinting spectrum and spectrogram method of discrimination |
Non-Patent Citations (2)
| Title |
|---|
| JIA-CHUAN HSU ET AL.: "Identification of Recombinant Insulin Analogues by Peptide Mapping Method", 《JOURNAL OF FOOD AND DRUG ANALYSIS》 * |
| 张培培 等: "胰岛素的HPLC肽图谱分析", 《药物生物技术》 * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111351880A (en) * | 2020-04-01 | 2020-06-30 | 上海中科新生命生物科技有限公司 | Mass spectrum detection method for recombinant human insulin biological analysis based on immunoaffinity |
| CN111778231A (en) * | 2020-07-29 | 2020-10-16 | 珠海冀百康生物科技有限公司 | Purification method of lysyl endopeptidase |
| CN111948315A (en) * | 2020-08-13 | 2020-11-17 | 中国科学院长春应用化学研究所 | Sequence analysis method and identification method of insulin or insulin analogue |
| CN112763636A (en) * | 2020-12-07 | 2021-05-07 | 佛山汉腾生物科技有限公司 | Peptide map analysis method |
| CN112763636B (en) * | 2020-12-07 | 2022-04-19 | 佛山汉腾生物科技有限公司 | Peptide map analysis method |
| CN115808484A (en) * | 2023-01-18 | 2023-03-17 | 北京惠之衡生物科技有限公司 | Method for detecting residual lysyl endonuclease in insulin or insulin analogue |
| CN115808484B (en) * | 2023-01-18 | 2023-04-14 | 北京惠之衡生物科技有限公司 | Method for detecting residual lysyl endonuclease in insulin or insulin analogue |
| CN116046947A (en) * | 2023-01-28 | 2023-05-02 | 北京惠之衡生物科技有限公司 | Method for detecting residual lysyl endonuclease in insulin diglucer |
| CN116046947B (en) * | 2023-01-28 | 2023-06-02 | 北京惠之衡生物科技有限公司 | Method for detecting residual lysyl endonuclease in insulin diglucer |
| CN116908321A (en) * | 2023-06-21 | 2023-10-20 | 南京汉欣医药科技有限公司 | Protamine sulfate peptide map detection method |
| CN116908321B (en) * | 2023-06-21 | 2024-05-31 | 南京汉欣医药科技有限公司 | Protamine sulfate peptide map detection method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110297050B (en) | 2022-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110297050A (en) | A kind of discrimination method of insulin mass spectrum peptide figure and application | |
| Jeppsson et al. | Toward standardization of carbohydrate-deficient transferrin (CDT) measurements: I. Analyte definition and proposal of a candidate reference method | |
| Kahsai et al. | Monitoring protein conformational changes and dynamics using stable-isotope labeling and mass spectrometry | |
| CN111896651B (en) | Agkistrodon halys venom thrombin-like enzyme characteristic polypeptide and application thereof | |
| US7807401B2 (en) | Reagent for digestion of hemoglobin | |
| CN110736802B (en) | Method for quantitatively detecting α -glucosidase in honey by liquid chromatography-tandem mass spectrometry | |
| CN110045028A (en) | A kind of Preclinical metabolism and pharmacokinetics study mass spectrometric analysis method of Avastin | |
| Vainauskas et al. | Profiling of core fucosylated N-glycans using a novel bacterial lectin that specifically recognizes α1, 6 fucosylated chitobiose | |
| Klammt et al. | Functional analysis of cell‐free‐produced human endothelin B receptor reveals transmembrane segment 1 as an essential area for ET‐1 binding and homodimer formation | |
| Thevis et al. | New drugs and methods of doping and manipulation | |
| Fang et al. | Comparative analysis of intact glycopeptides from mannose receptor among different breast cancer subtypes using mass spectrometry | |
| CN106872591A (en) | A kind of composition, kit and its detection method identified for authenticity of hide glue | |
| CN106153785A (en) | A kind of online sample introduction of aflatoxin analyzes method | |
| CN110531015A (en) | The method and its application of infliximab concentration in a kind of detection serum | |
| CN106841497A (en) | For detecting colla carapacis et plastri testudinis, deer horn glue, donkey-hide gelatin and its composition of donkey hide derived components content, kit and detection method in adulterant glue | |
| Van Der Gugten et al. | Quantitation of insulin analogues in serum using immunoaffinity extraction, liquid chromatography, and tandem mass spectrometry | |
| CN111189940B (en) | Method for detecting soluble epoxide hydrolase by liquid chromatography-mass spectrometry | |
| CN110498838B (en) | Characteristic peptide segment for detecting FPGS (planar-repeats-GS) and GGH (GGH) protein expression level and application thereof | |
| CN102175804A (en) | Absolute quantitative method for biomass spectra of CYP450 enzyme hypotypes | |
| Olivares et al. | Reactivity of different LH and FSH standards and preparations in the world health organization matched reagents for enzyme-linked immunoassays of gonadotrophins | |
| CN106841437A (en) | Composition, kit and its detection method for detecting donkey hide derived components content in donkey-hide gelatin | |
| CN108333287A (en) | A kind of quantitative detecting method of Cornu Saigae Tataricae powder | |
| CN109358131B (en) | The rapid analysis method of monoclonal antibody N sugar sugar-type | |
| CN111983043B (en) | Method for detecting poloxamer residual quantity in recombinant human urokinase raw material for injection | |
| EP3405785A1 (en) | Bio-analytical method for insulin analogues |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |